87N Stock Chart & Stats
€17.20
€0.20(1.18%)
At close: 4:00 PM EDT
€17.20
€0.20(1.18%)
Day’s Range― - ―
52-Week Range€11.30 - €23.60
Previous CloseN/A
Volume0.00
Average Volume (3M)22.00
Market Cap
€4.80B
Enterprise Value€4.14K
Total Cash (Recent Filing)€112.73M
Total Debt (Recent Filing)€448.52M
Price to Earnings (P/E)34.7
Beta0.53
Next Earnings
Aug 04, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding49,709,717
10 Day Avg. Volume67
30 Day Avg. Volume22
Financial Highlights & Ratios
PEG Ratio2.50
Price to Book (P/B)3.15
Price to Sales (P/S)4.10
P/FCF Ratio218.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€19.97Price Target Upside16.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.53
Revenue Forecast (FY)€1.12B
Bulls Say, Bears Say
Bulls Say
Robust Revenue GrowthSustained, large top-line expansion indicates widening commercial adoption and scalable demand for core packaging and delivery products. Over 2–6 months this breadth supports fixed-cost absorption, investment payback on capacity builds, and stronger negotiating leverage with customers.
High-value Solutions Mix And GLP‑1 ExposureA rising share of high-value solutions and significant exposure to GLP‑1/biologics points to stickier, higher-margin revenue streams that require lengthy qualification. This structural mix shift supports sustainable margin upside and recurring program-level revenues over the medium term.
Manageable Leverage And Equity GrowthRelatively low leverage and a growing equity base provide financial flexibility to fund capacity investments and absorb cyclical shocks. This balance sheet position enables the company to pursue multi-year capex programs without immediate solvency pressure or aggressive refinancing risk.
Bears Say
Weak And Volatile Free Cash FlowDespite solid operating cash inflows, persistent negative and volatile free cash flow reflects heavy growth capex and uneven cash conversion. Over the coming months this constrains discretionary spending, raises reliance on external financing, and limits scope for shareholder returns.
Engineering Segment Demand SlumpA sharp, sustained decline in Engineering revenue exposes the firm to concentration risk in higher-growth BDS areas and creates timing uncertainty for recovery. Slower order cycles increase volatility in project-related revenue and lengthen payback on sales investments in that segment.
Margin Pressure From Depreciation, FX And TariffsRamp-related depreciation, currency headwinds and tariff costs are compressing segment margins even as volumes scale. These structural cost pressures, combined with a higher effective tax rate, can erode sustained margin expansion and delay conversion of revenue growth into durable net cash profits.
Stevanato Group News
87N FAQ
What was Stevanato Group’s price range in the past 12 months?
Stevanato Group lowest stock price was €11.30 and its highest was €23.60 in the past 12 months.
What is Stevanato Group’s market cap?
Stevanato Group’s market cap is €4.80B.
When is Stevanato Group’s upcoming earnings report date?
Stevanato Group’s upcoming earnings report date is Aug 04, 2026 which is in 4 days.
How were Stevanato Group’s earnings last quarter?
Stevanato Group released its earnings results on May 07, 2026. The company reported €0.11 earnings per share for the quarter, beating the consensus estimate of €0.103 by €0.007.
Is Stevanato Group overvalued?
According to Wall Street analysts Stevanato Group’s price is currently Undervalued.
Does Stevanato Group pay dividends?
Stevanato Group does not currently pay dividends.
What is Stevanato Group’s EPS estimate?
Stevanato Group’s EPS estimate is 0.13.
How many shares outstanding does Stevanato Group have?
Stevanato Group has 49,709,717 shares outstanding.
What happened to Stevanato Group’s price movement after its last earnings report?
Stevanato Group reported an EPS of €0.11 in its last earnings report, beating expectations of €0.103. Following the earnings report the stock price went down -5.627%.
Which hedge fund is a major shareholder of Stevanato Group?
Currently, no hedge funds are holding shares in DE:87N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stevanato Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€19.97 (16.11% Upside)
€19.97 (16.11% Upside)
Blogger Sentiment
Bullish
DE:87N Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $204.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.33%
12-Months-Change
Fundamentals
Return on Equity
0.30%
Trailing 12-Months
Asset Growth
18.58%
Trailing 12-Months
Company Description
Stevanato Group
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
87N Company Deck
87N Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong top-line growth, robust Biopharmaceutical & Diagnostic Solutions momentum (notably syringes, biologics and GLP1 exposure), expanding high-value solution mix, margin expansion on an adjusted basis, and clear progress on strategic capacity investments. Offsetting these positives were a sharp revenue decline in the Engineering segment, segment-level gross margin compression for BDS driven by ramp-related depreciation, FX and tariff headwinds, a higher tax rate, modest free cash flow in the quarter due to heavy growth capex, and slower order conversion cycles in Engineering. Management reiterated full-year guidance and emphasized demand-driven capacity investment and operational optimization.View all DE:87N earnings summaries87N Stock 12 Month Forecast
Average Price Target
€19.97
▲(16.11% Upside)